Earlier this month, the Food and Drug Administration of Guangdong Province released the list of products that it has approved. In this list, the medical grade ECG and blood pressure tracker for a smartwatch from Huawei also received approval.
According to an ITHome report, the Chinese tech giant’s technology making it on the list officially signifies the company’s entry into the field of medical equipments. As per the data from the State Food and Drug Administration, the Huawei smartwatch’s ECG sensor belongs in the second category of medical equipment, with its registration certificate number “20202071705.”
Back in May 2021, He Gang, the president of Huawei’s consumer business smartphone product line, stated that the company’s first smartwatch that supports blood pressure tracking has passed medical device registration tests. Furthermore, the company’s new technology will also start registered clinical trials with professional medical institutions within the next six months. According to the Guangdong Food and Drug Administration, the brand has three other medical devices that have entered the priority approval process.
This includes the wrist ECG blood pressure tracker (MLY-B10, MLY-B11), ECG analysis system (ECG-1), and heart rate disturbance analysis system (PPG-1). While the current generation of smart wearables include a number of health monitoring systems, these are not used for medical diagnoses. Additionally, only a few brands have obtained the second class certificate for medical equipments, namely Huawei, Apple, Huami, and Oppo.
RELATED:
- Huawei’s new Nova series smartphones launching on October 21, Nova 9, Nova 8i expected
- Another report hints at Huawei Mate 50 series launching next year
- Huawei signs agreement with Vodafone to build Europe’s first 5G smart railway port
- Huawei MateBook 14s with 2.5K 90Hz Display set to release globally, starting with UK on October 27
